AEON Biopharma, Inc. — Form S-1MEF
Filed July 13, 2026 · analyzed by the Registration Agent
S-1MEF
— Neutral
significance 52/100
What the filing says
AEON Biopharma filed Form S-1MEF on July 13, 2026 to register an additional $4,528,125 in securities (inclusive of $679,219 over-allotment option) under Rule 462(b), expanding its prior July 8, 2026 registration (File No. 333-297327). The offering comprises common shares or pre-funded warrants, each bundled with two-year and five-year milestone warrants to purchase additional shares, underwritten by Lake Street Capital Markets, LLC.
Why this rating
At $8.7M market cap, a $4.5M gross raise is ~52% of company value—material for funding but routine for early-stage biotech. Follow-on offerings with warrants are standard. No operational change disclosed.
See more from July 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.